By a News Reporter-Staff News Editor at Proteomics Weekly -- Data detailed on Proteomics have been presented. According to news reporting originating from Seoul, South Korea, by NewsRx correspondents, research stated, "Protein-cage nanoparticles are promising multifunctional platforms for targeted delivery of imaging and therapeutic agents owing to their biocompatibility, biodegradability, and low toxicity. The major advantage of protein-cage nanoparticles is the ability to decorate their surfaces with multiple functionalities through genetic and chemical modification to achieve desired properties for therapeutic and/or diagnostic purposes."
Our news editors obtained a quote from the research from the Korea Institute of Science and Technology, "Specific peptides identified by phage display can be genetically fused onto the surface of cage proteins to Promote the association of nanoparticles with a particular cell type or tissue. Upon symmetrical assembly of the cage, peptides are dustered on the surface of the cage protein in bunches. The resulting PBNC (peptide bunches on nanocage) offers the potential of synergistically increasing the avidity of the peptide ligands, thereby enhancing their blocking ability for therapeutic purposes. Here, we demonstrated a proof-of-principle of PBNCs, fusing the interleukin-4 receptor (IL-4R)-targeting peptide, AP-1, identified previously by phage display, with ferritin-L-chain (FTL), which undergoes 24-subunit assembly to form highly stable AP-1-containing nanocage proteins (AP1-PBNCs). AP1-PBNCs bound specifically to the IL-4R-expressing cell line, A549, and their binding and internalization were specifically blocked by anti-IL-4R antibody. AP1-PBNCs exhibited dramatically enhanced binding avidity to IL-4R compared with AP-1 peptide, measured by surface plasmon resonance spectroscopy. Furthermore, treatment with AP1-PBNCs in a murine model of experimental asthma diminished airway hyper-responsiveness and eosinophilic airway inflammation along with decreased mucus hyperproduction."
According to the news editors, the research concluded: "These findings hold great promise for the application of various PBNCs with ligand-specific peptides in therapeutics for different diseases, such as cancer."
For more information on this research see: Designed Nanocage Displaying Ligand-Specific Peptide Bunches for High Affinity and Biological Activity. ACS Nano, 2013;7(9):7462-7471. ACS Nano can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; ACS Nano - www.pubs.acs.org/journal/ancac3)
The news editors report that additional information may be obtained by contacting J.O. Jeon, Korea Inst Sci & Technol, Biomed Res Inst, Seoul 136791, South Korea. Additional authors for this research include S. Kim, E. Choi, K. Shin, K. Cha, I.S. So, S.J. Kim, E. Jun, D. Kim, H.J. Ahn, B.H. Lee, S.H. Lee and I.S. Kim (see also Proteomics).
Keywords for this news article include: Asia, Seoul, Peptides, Proteins, Proteomics, South Korea, Amino Acids, Nanoparticle, Nanotechnology, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC